Acceptability and efficacy of vaginal self-sampling for genital infection and bacterial vaginosis: A cross-sectional study

PLoS One. 2021 Nov 18;16(11):e0260021. doi: 10.1371/journal.pone.0260021. eCollection 2021.

Abstract

Background & aim: Screening for genital infection (GI) such as bacterial vaginosis (BV) and yeast infection, for sexually transmitted infection (STI), and for asymptomatic carriage of group B streptococcus (GBS) in pregnant women are common reason for medical appointments. The diagnosis and control of GIs, STIs, and GBS are major issues, for fertility and overall well-being of affected women. Conventional testing is performed using vaginal/cervical classical sampling (VCS); this procedure requires pelvic examination performed by health care professionals which raises concerns among women. Vaginal-self-sampling (VSS), as an alternative to VCS, might capture more women. The aim was first to show non-inferiority of VSS compared with VCS to screen for GIs, STIs, and GBS; second to determine the feasibility of VSS.

Methods: VSS and VCS from 1027 women were collected by health care professionals and simultaneously carried out on each patient. GIs, STIs, and GBS were systematically screened in both paired VSS and VCS samples. Non-inferiority of VSS compared with VCS was assessed using z statistic for binomial proportions.

Results: Prevalence of GIs were 39.7% using VSS and 38.1% using VCS (p = 0.0016). Prevalence of STIs was 8.5% (VSS) vs 8.1% (VCS) (p = 0.0087). Prevalence of GBS was 13.4% (VSS) and 11.5% (VCS) (p = 0.0001). Most participants (84%) recommended the use of VSS.

Conclusions: This study shows that VSS was not inferior to VCS for the detection of GIs, STIs, and GBS. This study provides evidence that VSS can be used as a universal specimen for detection of lower genital tract infections in women.

Study identification number: ID-RCB 2014-A01250-4.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cross-Sectional Studies
  • Female
  • France
  • Genitalia
  • Humans
  • Mass Screening / methods
  • Patient Acceptance of Health Care / psychology
  • Self-Testing
  • Specimen Handling / methods*
  • Urinary Tract Infections / diagnosis
  • Vaginal Diseases / diagnosis*
  • Vaginal Diseases / microbiology
  • Vaginosis, Bacterial / diagnosis*
  • Vaginosis, Bacterial / microbiology

Grants and funding

This work was supported by European Alphabio Laboratory and European Hospital of Marseille and two industrial companies, Roche Molecular Systems, Inc., and BioMérieux, for providing reagents. Roche Molecular Systems, Inc., supported Claire Camus for the preliminary presentation at the ECCMID congress 2017. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing the report. The corresponding author had full access to all study data and had final responsibility to submit for publication.